Systemic DNase I

About Xenetic Biosciences

Xenetic Biosciences is a publicly-traded biopharma company developing adjunctive cancer therapies based on its DNase I platform, which targets neutrophil extracellular traps (NETs) to overcome resistance to standard treatments. The company is strategically positioned in the high-value oncology space, with a focus on pancreatic cancer and other solid tumors, and is backed by a team with significant industry experience. Its strategy involves advancing its lead candidate into clinical trials while leveraging key partnerships with research institutions and manufacturing organizations.

About Xenetic Biosciences

Xenetic Biosciences is a publicly-traded biopharma company developing adjunctive cancer therapies based on its DNase I platform, which targets neutrophil extracellular traps (NETs) to overcome resistance to standard treatments. The company is strategically positioned in the high-value oncology space, with a focus on pancreatic cancer and other solid tumors, and is backed by a team with significant industry experience. Its strategy involves advancing its lead candidate into clinical trials while leveraging key partnerships with research institutions and manufacturing organizations.

Therapeutic Areas